1. Antibodies
  2. Homo sapiens
  3. EIF4G1

ENCAB000BFI

Antibody against Homo sapiens EIF4G1

Homo sapiens
K562
characterized to standards
Homo sapiens
any cell type or tissue
partially characterized
Status
released
Source (vendor)
MBLI
Product ID
RN002P
Lot ID
002
Characterized targets
EIF4G1 (Homo sapiens)
Host
rabbit
Clonality
polyclonal
Purification
affinity
Antigen description
KLH-conjugated synthetic peptide GEELLPPESTPIPANLS （480-496 aa)
Antigen sequence
GEELLPPESTPIPANLS
External resources

Characterizations

EIF4G1 (Homo sapiens)
Method: knockdown or knockout
Attachment from submitter
Attachment from submitters
compliant
Caption
Western blot following shRNA against EIF4G1 in K562 and HepG2 whole cell lysate using EIF4G1 specific antibody. Lane 1 is a ladder, lane 2 is K562 non-targeting control knockdown, lane 3 and 4 are two different shRNAs against EIF4G1. Lanes 5-8 follow the same pattern, but in HepG2. EIF4G1 protein appears as the green band, Tubulin serves as a control and appears in red.
Submitted by
Xintao Wei
Lab
Brenton Graveley, UConn
EIF4G1 (Homo sapiens)
Method: immunoprecipitation
Attachment from submitter
Attachment from submitters
not submitted for review by lab
Caption
IP-WB characterization of EIF4G1 specific antibody in K562 cell line . Lane 1 is 2.5% of five million K562 whole cell lysate Input, lane 2 is 2.5% of supernatant after immunoprecipitation and Lane 3 is 50% of IP enrichment using rabbit polyclonal Anti-EIF4G1(Human/Mouse)pAb. This antibody passes preliminary validation and will be further pursued for primary and secondary validation.
Submitted by
Balaji Sundararaman
Lab
Gene Yeo, UCSD
EIF4G1 (Homo sapiens)
K562
Method: immunoprecipitation
Attachment from submitter
Attachment from submitters
compliant
Caption
IP-Western Blot analysis of K562 whole cell lysate using EIF4G1 specific antibody. Lane 1 is 2.5% of 0.5mg input lysate, lane 2 is 2.5% of supernatant after immunoprecipitation and Lane 3 is 50% of IP enrichment using rabbit polyclonal Anti-EIF4G1 (Human/Mouse) pAb. This antibody passes preliminary validation and will be further pursued for primary and secondary validation.
Submitted by
Balaji Sundararaman
Lab
Gene Yeo, UCSD